Pfizer rated Strong Buy on oncology progress, Seagen deal, and attractive valuation with 6.38% yield.

Pfizer is seen as a strong buy due to its advancing oncology drug pipeline and the strategic acquisition of Seagen. The stock is attractively valued with a low price-to-earnings ratio of 8.35 and offers a 6.38% dividend yield, with a fair value estimated at $35 per share. Recent clinical successes in oncology and a promising obesity treatment pipeline support long-term growth despite patent expiration risks. Additionally, Pfizer's cost-cutting and pricing strategies like TrumpRx are improving profit margins and reducing macroeconomic risks, making it a compelling investment opportunity.